In this review, we aim to collect and summarise the current evidence about the possible involvement of RANK, RANKL, and OPG in MASLD pathophysiology, highlighting the potential therapeutic implications that emerge from the studies. The gene discussed is TNFSF11; the disease is metabolic dysfunction-associated steatotic liver disease.